Clomid and Rosuvastatin Interaction: What Women Need to Know Before Combining These Drugs

Why a Woman Taking Rosuvastatin Would Also Need Clomid

These two drugs coexist most often in one specific clinical scenario: a woman with polycystic ovary syndrome (PCOS) who also has dyslipidemia. That overlap is not rare. Approximately 70 percent of women with PCOS have at least one feature of metabolic syndrome, and dyslipidemia is present in up to 70 percent of PCOS cases, often driving a physician to prescribe a statin.

Rosuvastatin is one of the most potent statins for lowering LDL cholesterol, reducing LDL-C by 45-55 percent at the 10-20 mg dose range. Clomiphene citrate remains a first-line ovulation-induction agent for women with PCOS or unexplained anovulation, typically dosed at 50-150 mg orally on cycle days 3-7 or 5-9. The question of whether these two drugs interact at a pharmacological level, and what to do clinically when a woman needs both, deserves a precise answer.

PCOS: The Condition That Puts Both Drugs in the Same Prescription Bag

PCOS affects 8-13 percent of women of reproductive age worldwide. The Rotterdam criteria require two of three features: oligo- or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. The anovulation drives the need for clomiphene. The associated insulin resistance and dyslipidemia can drive the need for a statin.

A reproductive endocrinologist may have a patient on rosuvastatin for cardiovascular risk reduction who then pivots to fertility treatment. The prescriber needs to know exactly what happens when these two drugs share the same body.

Metabolic Syndrome and Cardiovascular Risk in Women With PCOS

Women with PCOS have a significantly elevated lifetime cardiovascular risk. The ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group notes that PCOS is associated with an adverse cardiovascular risk profile, including elevated triglycerides, low HDL, and elevated small dense LDL particles. Statins are a logical tool. The tension arises because the same women pursuing fertility treatment may be in the exact reproductive-age window where statin therapy, if continued into pregnancy, poses embryofetal risk.

The Pharmacokinetic Interaction: Mechanism in Detail

This is the core clinical question. Does clomiphene change how rosuvastatin behaves in your body, or vice versa?

Rosuvastatin's Transport Pathway

Rosuvastatin is not primarily metabolized by cytochrome P450 enzymes to a clinically meaningful degree. Approximately 10 percent of rosuvastatin undergoes CYP2C9-mediated metabolism, making it largely CYP-independent compared to other statins like simvastatin or atorvastatin. Its systemic exposure is governed by hepatic uptake transporters, specifically OATP1B1 and OATP1B3, and by the efflux transporter BCRP (breast cancer resistance protein, encoded by ABCG2). Drugs that inhibit these transporters, such as cyclosporine or certain antivirals, can raise rosuvastatin plasma concentrations dramatically and increase myopathy risk.

Clomiphene's Metabolic Profile

Clomiphene citrate is metabolized primarily by CYP3A4 and to a lesser extent CYP2D6. It is a selective estrogen receptor modulator (SERM) that blocks hypothalamic estrogen receptors, reducing negative feedback and triggering a rise in FSH and LH. Clomiphene is not a clinically significant inhibitor of OATP1B1, OATP1B3, or BCRP at therapeutic doses. It is also not a meaningful inhibitor or inducer of CYP2C9, the minor pathway by which rosuvastatin is partially metabolized.

The Net Pharmacokinetic Verdict

No published pharmacokinetic study has demonstrated a direct, clinically significant drug-drug interaction between clomiphene citrate and rosuvastatin at therapeutic doses. Standard DDI screening databases classify this combination as having no well-documented pharmacokinetic interaction requiring dose adjustment from a transporter or enzyme standpoint. This does not mean the combination is risk-free. The risks are pharmacodynamic and, most critically, pregnancy-related.

The WomanRx DDI Framework for This Pair:

| Interaction Axis | Verdict | Clinical Action | |---|---|---| | CYP enzyme overlap | Minimal (different primary enzymes) | No dose change needed | | Transporter competition (OATP/BCRP) | Not observed at therapeutic doses | No dose change needed | | Pharmacodynamic (shared toxicity) | Low (different organ targets) | Routine LFT monitoring | | Pregnancy risk | HIGH (rosuvastatin Category X) | Stop statin before conception attempt | | Hormonal axis effects | Possible (see below) | Lipid panel timing matters |

Pharmacodynamic Considerations: What Each Drug Does to Your Hormones

Clomiphene's Effect on Lipids

Clomiphene has estrogenic and anti-estrogenic properties depending on the tissue. In the liver, estrogen receptor agonism tends to reduce LDL-C and increase HDL-C and triglycerides. Short-cycle clomiphene use (5 days per month) is unlikely to meaningfully alter a patient's lipid panel, but the underlying hormonal changes from induced ovulation, particularly the estrogen surge around mid-cycle, may produce transient lipid shifts. Clinically, these are not large enough to require statin dose adjustment within a single treatment cycle.

Rosuvastatin's Effect on Female Hormones

Statins as a class have raised questions about potential effects on steroidogenesis, because cholesterol is the precursor for all steroid hormones. A 2016 systematic review in Fertility and Sterility found that statin use was associated with reduced androgen levels in women with PCOS, which could theoretically be a benefit in PCOS management but has also raised theoretical concerns about whether statins impair ovarian steroidogenesis in women trying to conceive. The clinical evidence on whether rosuvastatin at standard doses impairs clomiphene-induced ovulation is thin. This is an area where data in women are genuinely limited, and extrapolation from preclinical studies should be interpreted cautiously.

Muscle and Liver: Shared Monitoring Targets

Both drugs independently carry hepatic signals. Clomiphene rarely causes liver enzyme elevations; rosuvastatin can cause transaminase elevations in roughly 1 percent of patients at doses of 40 mg, and myopathy occurs at a rate of approximately 0.1 percent with rosuvastatin at standard doses. Adding any drug that competes for hepatic processing warrants a baseline liver function panel before starting, though the combination of clomiphene and rosuvastatin does not multiply hepatotoxicity risk in the way that, say, niacin plus a statin does.

Pregnancy, Lactation, and Contraception: The Non-Negotiable Section

This section is mandatory for any drug article on WomanRx. Both drugs have significant pregnancy and lactation implications, and this is where the highest clinical stakes lie.

Rosuvastatin in Pregnancy: Category X, Full Stop

The FDA label for rosuvastatin (Crestor) designates it as Pregnancy Category X. Statins inhibit HMG-CoA reductase, an enzyme critical for cholesterol synthesis. Cholesterol is essential for fetal cell membrane development, myelination, and steroid hormone production. Animal studies with rosuvastatin have shown fetal skeletal malformations and developmental toxicity. Human data on rosuvastatin specifically in pregnancy are limited, but the class-level concern is well-established.

The label states plainly: "Rosuvastatin is contraindicated in women who are pregnant or may become pregnant." If pregnancy occurs during rosuvastatin therapy, the drug must be discontinued immediately and the patient counseled.

The Timing Problem for Women Using Clomid

Here is where the interaction becomes clinically urgent. A woman using clomiphene citrate is, by definition, attempting to become pregnant. She and her prescribers must have a clear plan for rosuvastatin discontinuation BEFORE the first clomiphene cycle begins.

Standard clinical guidance from lipid specialists is to stop rosuvastatin at least one full menstrual cycle (approximately 4 weeks) before attempting conception. Given rosuvastatin's elimination half-life of approximately 19 hours, systemic clearance occurs within 4-5 days, but the precautionary period of one month accounts for early embryonic development that may occur before a pregnancy test is positive.

Clinical sequence for women transitioning off rosuvastatin to start Clomid:

1. Confirm baseline lipid panel and liver function tests.
2. Stop rosuvastatin at least 4 weeks before the planned first Clomid cycle.
3. Discuss alternative lipid management during the conception attempt (dietary changes, omega-3 fatty acids, bile acid sequestrants if LDL is very high and cardiovascular risk is significant).
4. Do not restart rosuvastatin until pregnancy is ruled out each cycle or until breastfeeding is complete.
5. If pregnancy is confirmed, contact the prescribing physician immediately; do not restart statin.

Rosuvastatin and Lactation

Rosuvastatin is present in human breast milk. The FDA label states it is contraindicated during breastfeeding because of the potential for serious adverse reactions in nursing infants, including disruption of infant cholesterol metabolism. Statin therapy should not be resumed until breastfeeding is discontinued.

Clomiphene in Pregnancy

Clomiphene citrate is used to induce ovulation, not to support a pregnancy. Once conception occurs, clomiphene is stopped. The FDA label for clomiphene citrate notes that animal studies have shown teratogenic and embryotoxic effects at doses producing exposure levels similar to human therapeutic doses. There is no indication for clomiphene use during an established pregnancy, and inadvertent exposure in early pregnancy warrants immediate cessation and discussion with a physician.

Clomiphene and Lactation

Clomiphene has anti-estrogenic activity and may suppress lactation by reducing estrogen signaling needed to maintain milk supply. Women who have recently delivered and are breastfeeding should not use clomiphene for ovulation induction; this is not a postpartum tool for lactating women.

Who Is This Combination Right For, and Who Should Avoid It?

Women Who May Reasonably Use Both (at Different Times)

• Women with PCOS and dyslipidemia who are preparing for a fertility cycle: rosuvastatin may be appropriate before the conception attempt, then stopped.
• Women with metabolic syndrome and anovulatory infertility who need short-term lipid management between fertility cycles.
• Women whose cardiovascular risk is high enough that a brief statin course is warranted, with a clear washout plan documented in the chart.

Women Who Should Not Use Both Simultaneously

• Any woman who is actively trying to conceive in the current cycle should not be taking rosuvastatin at the same time. The drugs should not overlap.
• Women with a history of statin-induced myopathy or rhabdomyolysis: adding any new drug that might slow hepatic clearance increases risk, even if the theoretical interaction with clomiphene is low.
• Women who are pregnant or who may be pregnant: both clomiphene and rosuvastatin are contraindicated once pregnancy is confirmed.

Life-Stage Breakdown

Reproductive years (18-40), trying to conceive: This is the primary group. The clinical goal is sequential use, not concurrent use. Rosuvastatin off before Clomid starts.

Perimenopause (40-51): Clomiphene is less commonly used for fertility in perimenopause, though it is occasionally trialed. Cardiovascular risk rises in perimenopause, making statin use more likely. The same stop-before-conception rule applies if any fertility attempt is planned.

Post-menopause: Clomiphene has no fertility role post-menopause. Rosuvastatin is commonly used for cardiovascular risk. No interaction concern applies in this life stage.

Monitoring Protocol: What Your Doctor Should Check

No universal guideline exists specifically for the clomiphene-rosuvastatin combination, because the direct pharmacokinetic interaction is not classified as clinically significant. The monitoring below draws from the ASRM Practice Committee guidelines on ovulation induction and standard statin monitoring guidance.

Before Starting Clomid (While on or Coming Off Rosuvastatin)

• Fasting lipid panel (baseline, to plan statin discontinuation timing)
• Liver function tests (ALT, AST)
• Fasting glucose or HbA1c (especially in PCOS patients with insulin resistance)
• Transvaginal ultrasound (antral follicle count, baseline ovarian morphology)
• Confirm negative pregnancy test

During Each Clomid Cycle

• Mid-cycle ultrasound to assess follicle development (day 12-14 for a day 3-7 protocol)
• LH surge monitoring or trigger shot timing
• Rosuvastatin must remain stopped throughout

After Completing Fertility Treatment

• Recheck lipid panel 6-8 weeks after resuming statin (if not pregnant and not breastfeeding)
• Myopathy screening if any new muscle pain, weakness, or dark urine develops (CK level)

What to Tell Your Doctors: The Coordination Problem

Women using clomiphene often see a reproductive endocrinologist or OB-GYN for fertility and a separate primary care physician or cardiologist for lipid management. These two prescribers may not be communicating with each other. Fragmented prescribing is a documented patient safety issue in women's health, particularly for women with complex conditions like PCOS who span multiple specialty teams.

You should proactively tell each prescriber the full medication list, including supplements. Specifically:

• Tell your fertility doctor that you are on or were recently on rosuvastatin, and when you stopped it.
• Tell your lipid or primary care doctor that you are starting or have started clomiphene and that you need a plan for managing your LDL-C during the conception attempt.
• Ask explicitly: "Is it safe to stop rosuvastatin for the duration of my fertility treatment, and what is the plan if I become pregnant?"

The ACOG Committee Opinion on preconception care recommends a full medication review at least 3 months before a planned pregnancy, specifically to identify teratogenic drugs and plan discontinuation. Rosuvastatin is a textbook case.

The Evidence Gap: What We Do and Do Not Know

Women have been historically underrepresented in pharmacokinetic and drug-drug interaction trials. The data gaps here are real and worth naming.

No published clinical trial has directly studied the pharmacokinetic or pharmacodynamic interaction of clomiphene citrate and rosuvastatin in women. The conclusions in this article are based on:

• Known metabolic pathways for each drug (CYP and transporter profiles from FDA labels and published PK studies)
• Class-level statin data on steroidogenesis
• PCOS-specific statin literature
• Reproductive safety data from animal and human pregnancy registries

What is directly studied: rosuvastatin's OATP/BCRP transporter profile; clomiphene's CYP3A4 metabolism; statin use in PCOS; statin teratogenicity in pregnancy registries.

What is extrapolated: the absence of a meaningful clomiphene-rosuvastatin PK interaction is inferred from the drugs' non-overlapping metabolic pathways, not from a head-to-head study. If future interaction studies are conducted, these conclusions should be revisited.

As noted by the ASRM Practice Committee, "evidence-based guidelines for fertility treatment must acknowledge that many drug interactions in reproductive medicine are understudied, and clinical judgment must fill these gaps."

Practical Counseling Points for Women

A brief but specific list, written in plain language for the conversation you might have with your prescriber or for self-advocacy purposes:

• Rosuvastatin must stop before your first Clomid cycle. At least one full month before.
• Do not restart rosuvastatin until you know you are not pregnant and you are not breastfeeding.
• If you forget and take rosuvastatin after a positive pregnancy test, call your doctor that day. Do not wait.
• Muscle pain or weakness while on rosuvastatin should always be reported. This is true even without clomiphene in the picture.
• A low-saturated-fat diet, regular aerobic exercise, and omega-3 supplementation (1-2 g DHA/EPA per day) may help maintain acceptable LDL-C during the statin-free window of your fertility treatment. These are not replacements for rosuvastatin in high-risk patients, but they are reasonable bridges for most women with moderate dyslipidemia.
• Bile acid sequestrants such as cholestyramine are not absorbed systemically and are considered safe in pregnancy if lipid management is truly necessary during the conception window. Discuss this option with your prescriber.